UT Austin Develops 2-Part Cancer Compound That Kills Most Melanoma Cells in Mice

2 articles · Updated · SciTechDaily · Aug 16

Nature Chemical Biology published UT Austin work showing an experimental compound killed most melanoma cells in mice while sparing many noncancerous cells, with lab activity also seen in human melanoma, leukemia, breast, lung, liver and neuroblastoma cells.
Two linked components drive the effect: XJ-4-85 binds PFKL to accelerate glycolysis, then releases a second agent that targets CPT2, cutting off fatty-acid use and overwhelming cancer metabolism on two fronts.
Researchers say the small-molecule design could act as a chemical counterpart to antibody-drug conjugates, potentially easier to manufacture and able to reach proteins inside cells rather than only on cell surfaces.
Human testing remains distant, and the team said the study may open a broader platform for similar electrophile-drug conjugates, or EDCs, with possible uses beyond cancer.

Sources

Could this tiny chemical Trojan horse finally solve the fatal flaws of a 16 billion dollar cancer drug industry?

Will forcing cancer cells into metabolic overdrive inadvertently trigger dangerous side effects like lactic acidosis in human patients?

If a tumor's backup fuel is destroyed while its main engine redlines, how long until the cancer cell completely burns out?

2 total